Minerva Neurosciences, Inc. SEC filings NERV
Minerva Neurosciences, Inc. has 645 filings in SEC EDGAR's recent list, going back to Feb 14, 2014. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 3, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2026 | Jun 3, 2026 |
| DEF 14A | Proxy statement | Nov 24, 2025 | Dec 22, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 14, 2025 | Dec 22, 2025 |
| DEFA14A | Additional proxy material | Oct 22, 2024 | — |
| DEF 14A | Proxy statement | Oct 22, 2024 | Dec 5, 2024 |
| DEFA14A | Additional proxy material | Aug 15, 2023 | — |
| DEF 14A | Proxy statement | Aug 15, 2023 | Sep 27, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEF 14A | Proxy statement | Apr 26, 2022 | Jun 10, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2022 | Jun 10, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 11, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2021 | Jun 11, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 19, 2020 |
| DEFA14A | Additional proxy material | Apr 17, 2019 | — |
| DEF 14A | Proxy statement | Apr 17, 2019 | May 31, 2019 |
| DEFA14A | Additional proxy material | Apr 24, 2018 | — |
| DEF 14A | Proxy statement | Apr 24, 2018 | Jun 7, 2018 |
| DEFA14A | Additional proxy material | Apr 18, 2017 | — |
| DEF 14A | Proxy statement | Apr 18, 2017 | Jun 1, 2017 |
| DEFA14A | Additional proxy material | Apr 29, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 16, 2016 |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 17, 2015 |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NERV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Burlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1598646
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.